MGAT2

Across TCGA pan-cancer cohorts, MGAT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MGAT2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MGAT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGAT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where MGAT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.224	0.794	.002	22	view →
LUAD	OS	Tertile	II,III,IV	0.893	0.350	.008	4	view →
GBM	OS	Median	All	0.432	0.640	.039	3	view →
PDAC	OS	Median	All	0.324	0.511	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MGAT2–CCRCC (DFS)

Open the CCRCC breakdown →